

ATTORNEY DOCKET NO.: PCT0063
Customer No.: 26839
Application No. 09/554,784

IN THE CLAIMS:

Please cancel claims 4-10 without prejudice or disclaimer to the subject matter contained therein and add the following new claims therefore:

- SUB E, 1
- [--] 1. (new) A composition comprising the monoclonal antibody of any one of claims 1 to 3, or a fragment thereof, and an autoantigen, peptide fragment of an autoantigen, or a modified form of an autoantigen.
12. (new) The composition of claim 11, wherein the autoantigen is myelin basic protein, collagen type II, human cartilage glycoprotein 39, a heat shock protein, insulin, glutamate decarboxylase, or α -fodrin.
13. (new) The composition of claim 12, wherein the autoantigen is a heat shock protein that stimulates type 2 cytokine producing regulatory T-cells.
- C 2
14. (new) A composition comprising the monoclonal antibody of any one of claims 1 to 3, or a fragment thereof, and a second monoclonal antibody that binds to a costimulatory molecule on T-cells or antigen presenting cells.
- SUB D, 1
15. (new) The composition of claim 13, wherein the costimulatory molecule bound by the second monoclonal antibody is CD40, CD40L, CD80, or CD86.
- SUB E, 1
16. (new) A composition comprising the monoclonal antibody of any one of claims 1 to 3, and a physiologically acceptable excipient, diluent, stabilizing agent, or carrier.
17. (new) A composition comprising the composition of claim 12 and a physiologically acceptable excipient, diluent, stabilizing agent, or carrier.
18. (new) A composition comprising the composition of claim 14 and a physiologically acceptable excipient, diluent, stabilizing agent, or carrier.

ATTORNEY DOCKET NO.: PCT0063
Customer No.: 26839
Application No. 09/554,784

- S.B.
E-1
19. (new) A method of inhibiting a Th1 type response in an autoimmune disease comprising administering an amount of the monoclonal antibody of any one of claims 1 to 3 sufficient to inhibit a Th1 type response in a patient in need of such treatment.
20. (new) A method of inhibiting a Th1 type responses in an autoimmune disease comprising administering an amount of the monoclonal antibody of any one of claims 1 to 3 sufficient to inhibit a Th1 type response in a patient in need of such treatment in combination with an autoantigen or a second monoclonal antibody that binds to a costimulatory molecule on T-cells or antigen presenting cells.
21. (new) A method of inhibiting a Th1 type response in an autoimmune disease comprising administering an amount of the composition of claim 11 sufficient to inhibit a Th1 type response in a patient in need of such treatment.
22. (new) A method of inhibiting a Th1 type response in an autoimmune disease comprising administering an amount of the composition of claim 14 sufficient to inhibit a Th1 type response in a patient in need of such treatment.]

IN THE ABSTRACT:

C3 Applicants submit the attached abstract.

REMARKS

Claims 1-3 and 11-22 are now pending in this application. Applicants have cancelled claims 4-10 without prejudice or disclaimer to the subject matter contained therein, and substituted claims 11-22. Support for these new claims may be found in the specification as a whole and claims 4-10 specifically. No new matter has been entered by this amendment and these claims retain the same unity of invention as the previous claims.